TERNライブシグナル | Getagraph.comで利益を最大化

売る 106490 min ago

@ $6.86

発行日: 14 2月 2024 @ 23:30

リターン: -28.43%

前回のシグナル: 2月 10 - 05:54

前回のシグナル: 買う

リターン: -0.72 %

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	495 961
平均出来高	896 139
時価総額	317.44M
EPS	$0 ( 2024-03-25 )
次の収益日	( $-0.360 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.87
ATR14	$0.00900 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Vivo Opportunity, Llc	Sell	136 255	Common Stock
2024-04-02	Vivo Opportunity, Llc	Sell	76 346	Common Stock
2024-04-03	Vivo Opportunity, Llc	Sell	103 870	Common Stock
2024-04-01	Vivo Opportunity, Llc	Sell	39 411	Common Stock
2024-04-02	Vivo Opportunity, Llc	Sell	22 084	Common Stock

INSIDER POWER
68.20
Last 96 transactions
Buy: 25 215 859 \| Sell: 2 318 163

ボリューム相関

長: 0.60 (weak)

短: -0.48 (neutral)

Signal:(69.062) Neutral

Terns Pharmaceuticals, 相関

10 最も正の相関
SVAC	0.926
EMLD	0.908
ARTEU	0.905
CFFE	0.905
PAIC	0.898
LRMR	0.898
GDST	0.897
ARIZ	0.896
CARG	0.892
LQDA	0.891

10 最も負の相関
BCAB	-0.929
ATAI	-0.923
CUTR	-0.923
SMFL	-0.92
GMAB	-0.919
MYSZ	-0.919
SRAC	-0.916
SPCX	-0.908
VFF	-0.906
NCBS	-0.903

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Terns Pharmaceuticals, 相関 - 通貨/商品

-0.10
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.30
( neutral )

-0.14
( neutral )

-0.41
( neutral )

Terns Pharmaceuticals, 財務諸表

Annual	2023
収益:	$0
総利益:	$-881 000 (0.00 %)
EPS:	$-1.270

FY	2023
収益:	$0
総利益:	$-881 000 (0.00 %)
EPS:	$-1.270

FY	2022
収益:	$0
総利益:	$-1.03M (0.00 %)
EPS:	$-1.670

FY	2021
収益:	$1.00M
総利益:	$0.00 (0.00 %)
EPS:	$-2.21

Financial Reports:

No articles found.

Terns Pharmaceuticals,

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.